# RNN 1st Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations
May 3, 2018
at 12-oct-2018
VRTX
Model's trade recommendations 0.40% Return for period
3.16% Annual return
$38.09B Market Cap
β 1.44
VRTX
Model (following trade recommendations)VRTX
Underlying stockS&P 500
Index- STRONG BUY Analysts consensus recommendation
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Sept. 30, 2015.
Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 250M |
| P/E | 124.56 |
| Shares Outstanding | 255M |
| % Held by Insiders | 1.80% |
| % Held by Institutions | 94.80% |
| EPS (last reported FY) | $0.80 |
| EPS (last reported Q) | $0.54 |
| EPS, estimated (last reported Q) | $0.28 |
| Total revenues | $2 B |
| Net income | $0 B |